App-Quantinova.ai

Cerebral Venous Sinus Thrombosis in Pediatric Acute Lymphoblastic Leukemia: Risk Factors and Long-Term Outcomes

L. Johnson-Bishop - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute lymphoblastic leukemia

N/A

Comparison between Intermittent Bolus versus Continuous Intravenous Infusion of Tranexamic Acid in Hematological Disorders with Thrombocytopenia (BRAVE Trial)

B. Poojitha - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Tranexamic acid

Deep venous thrombosis in a child with Down syndrome as a presenting manifestation of acute lymphoblastic leukemia

A. Jovanovska - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute lymphoblastic leukemia

N/A

PREVAPIX-ALL: Phase 3 Study of the Safety and Efficacy of Apixaban for Thromboprophylaxis versus Standard of Care in Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia or Lymphoma (ALL/LL)

S. O'Brien - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Asparaginase

Venous thromboembolism in a large series of pediatric patients with acute lymphoblastic leukemia. Risk factors and use of prophylaxis.

R. Berrueco - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute lymphoblastic leukemia

Heparin

Investigating the cellular uptake of liposomal delivery system using cellular models of lymphoma

Joyce Edlyne Chima Bom - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Tesmilifene

Gene expression profiles associated with induction treatment response in pediatric patients with acute lymphoblastic leukemia type B

Yulieth X. Torres-Llanos - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

ADAM10-targeting CAR-T cells inhibit colon cancer cell growth in vivo

Elaheh Rohani Rad - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Disruption of cell-intrinsic checkpoint regulator CTLA-4 in CD19 directed CAR T cells provides clinical efficacy in CLL patients

Sangya Agarwal - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

HOXA9 demonstrates allelic imbalance in KMT2A-rearranged infant acute lymphoblastic leukemia

Sarah E. Mc Dermott - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Tolinapant (ASTX660 enhances the anti-leukemic activity of Venetoclax and Dexamethasone in T cell acute lymphoblastic leukemia (T-ALL

Priyanka Sharma - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Dexamethasone

THE ROLE OF DERMATOLOGISTS ON THE DIAGNOSIS OF LEUKEMIAS SUCH AS BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)

Nerea Mohino-FarrÃ© - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

N/A

Acute Lymphoblastic Leukemia (ALL) Presenting as Spontaneous Tumor Lysis Syndrome with Acute Kidney Injury (AKI) Requiring Hemodialysis (HD) in an Elderly Patient

Sherida Edding - National Kidney Foundation (NKF) , 2021

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Acute lymphoblastic leukemia

N/A

IL-12 abrogates mechanisms of immune suppression by B-ALL

Rae Hunter - American Association of Immunologists (AAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

IL-12

BATF3/MYC axis drives hyper-proliferation of TET2 deficient CAR T cells

Nayan Jain - American Association of Immunologists (AAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Evaluating the Potential of Harnessing Anti-Leukemia T cells for Treating T-ALL

Todd A Triplett - American Association of Immunologists (AAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Obese microenvironments attenuate the efficacy of endogenous and CD19-directed CAR T-cells

Raira Silva Ank - American Association of Immunologists (AAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

The Role of Truncated SOS1 in Acute Lymphoblastic Leukemia

Lynn M Heltemes Harris - American Association of Immunologists (AAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute lymphoblastic leukemia

EXON 8

Common trajectories of highly effective CD19-specific CAR T cells identified by endogenous T cell receptor lineages

Jeremy Chase Crawford - American Association of Immunologists (AAI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Overcoming AML T cell therapy barriers with engineered proteins

Aitong Ruan - American Association of Immunologists (AAI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Filters

2187 Abstracts